



## Rosiglitazone and cardiovascular risk - NPS fact sheet



A recent meta-analysis has raised concerns about a potential increase in cardiovascular risk among patients treated with rosiglitazone. NPS has released a fact sheet, [Rosiglitazone and cardiovascular risk](#), which discusses this issue.

**Date published:** 01/08/2007

The information contained in this material is derived from a critical analysis of a wide range of authoritative evidence. Any treatment decisions based on this information should be made in the context of clinical circumstances of each patient.

(c) NPS; not to be copied, republished, sold or redistributed without the written consent of NPS. Today's Date: 17/7/2008